M2R
0.003
50%
CNJ
0.02
-73.7%
RAD
0.026
44.4%
NAE
0.002
-33.3%
MEM
0.004
33.3%
SPX
0.002
-33.3%
VKA
0.009
28.6%
RKB
0.003
-25%
RDN
0.005
25%
TAR
0.018
-25%
DRO
2.83
23%
OEL
0.004
-20%
NFM
0.017
21.4%
TDO
0.14
-17.6%
4DX
2.95
20.9%
BMO
0.033
-15.4%
VAR
0.006
20%
AX8
0.006
-14.3%
PTX
0.11
18.3%
BNL
0.006
-14.3%
BLU
0.007
16.7%
ECS
0.006
-14.3%
GLL
0.007
16.7%
ENV
0.006
-14.3%
MGL
0.245
16.7%
SER
0.006
-14.3%
VSR
0.035
16.7%
AZY
0.537
-13.4%
EOS
7.44
15.2%
ALM
0.007
-12.5%
BKB
0.8
15.1%
MML
0.028
-12.5%
SNX
0.031
14.8%
PL9
0.007
-12.5%
HPG
1.385
14.5%
SRJ
0.014
-12.5%
CLX
2.15
13.2%
GG1
0.185
-11.9%
MQR
0.009
12.5%
D3E
0.305
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PYC Therapeutics (ASX:PYC): Reports vision improvement in multiple RP11 patients

PYC Therapeutics (ASX:PYC) has developed the only clinical-stage investigational drug candidate designed specifically for patients with the blinding eye disease Retinitis Pigmentosa type 11 (RP11).

👁️ PYC recently reported an improvement in vision in 2 patients with RP11
📣 PYC will announce further results from the ongoing multiple dose studies of VP-001 in Q4 2024
🧪 PYC is now preparing for a registrational trial that will be designed to support a new drug application and commercial launch of this drug candidate 4

ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240812/pdf/066j27mrjnft47.pdf